Medpace (NASDAQ:MEDP) Announces FY 2026 Earnings Guidance

Medpace (NASDAQ:MEDP) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided EPS guidance of 17.970-18.320 for the period, compared to the consensus EPS estimate of 17.680. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion.

Medpace Price Performance

Shares of MEDP stock traded up $11.46 during trading on Friday, reaching $665.42. The company’s stock had a trading volume of 122,358 shares, compared to its average volume of 331,820. The company has a market capitalization of $18.57 billion, a price-to-earnings ratio of 39.06, a P/E/G ratio of 2.96 and a beta of 1.18. Medpace has a 1-year low of $373.00 and a 1-year high of $684.52. The stock’s 50-day moving average price is $609.84 and its 200 day moving average price is $536.74.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, October 21st. The company reported $4.84 earnings per share for the quarter, beating the consensus estimate of $4.44 by $0.40. Medpace had a net margin of 18.24% and a return on equity of 104.17%. The firm had revenue of $716.00 million for the quarter, compared to analysts’ expectations of $714.47 million. During the same quarter last year, the company earned $3.86 earnings per share. The firm’s revenue was up 8.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Medpace will post 17.54 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. BMO Capital Markets boosted their target price on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research note on Friday, July 24th. Jefferies Financial Group restated a “hold” rating on shares of Medpace in a research note on Monday, September 14th. TD Cowen upped their price objective on Medpace from $492.00 to $673.00 and gave the stock a “hold” rating in a research report on Friday. Mizuho set a $730.00 price objective on Medpace in a research report on Friday. Finally, Truist Financial set a $633.00 price objective on Medpace in a report on Friday. Three equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $642.91.

Insiders Place Their Bets

In other Medpace news, CEO August Troendle sold 21,966 shares of Medpace stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $625.47, for a total transaction of $13,739,074.02. Following the transaction, the chief executive officer owned 338,225 shares of the company’s stock, valued at $211,549,590.75. The trade was a 6.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders have sold 336,140 shares of company stock valued at $208,008,328 over the last three months. 20.50% of the stock is owned by insiders.

Medpace News Roundup

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Third-quarter results exceeded expectations. Medpace reported adjusted earnings of $4.84 per share versus the $4.44 consensus estimate, while revenue of $716 million slightly surpassed forecasts and rose 8.5% year over year. Medpace Q3 Earnings and Revenues Beat Estimates
• Positive Sentiment: Management issued an above-consensus outlook. Fiscal 2026 EPS guidance of $17.97-$18.32 is above the $17.68 analyst estimate, while revenue guidance of $2.8 billion-$2.9 billion is at least in line with expectations. Medpace Forecasts 2026 EPS and Buyback
• Positive Sentiment: Backlog and new business support future visibility. Third-quarter net new business awards reached $873 million, and ending backlog rose 5.6% year over year to $3.2 billion. Medpace Three Key Takeaways
• Positive Sentiment: The new $1 billion buyback signals management confidence and could support earnings per share by reducing the number of shares outstanding. Medpace Gets $1 Billion Buyback Authorization
• Neutral Sentiment: Analysts raised targets but remained cautious. TD Cowen lifted its target to $673 and Deutsche Bank raised its target to $650; both maintained “hold” ratings, suggesting the improved outlook is largely reflected in the share price. Deutsche Bank Raises Medpace Price Target
• Negative Sentiment: Valuation remains a concern. Commentary questioning whether Medpace is still overvalued, combined with its elevated earnings multiple, helps explain why the stock initially slipped despite the earnings beat and strong outlook. Medpace Valuation Commentary

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace’s services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.